At the end of 2022, it’s estimated that life sciences companies invested $45 billion in AI-mediated drug discovery and collaborations with AI companies. It’s no secret that AI is driving unprecedented innovation across drug discovery, diagnostics, and patient care.
It is also introducing complexities for life sciences companies, including new regulations – there were 200 pieces of AI regulations introduced in the U.S. in 2023 alone! – how to deal with hallucinations, data privacy and security, and more.
As AI transitions from a "nice to have" to an essential tool, companies and their leaders should develop a clear vision and strategy for harnessing AI's potential, followed by establishing the foundational elements necessary for its widespread implementation.
Wherever you are on this journey, we’ve curated our top-performing content on the topic of AI and GenAI 👀
GenAI C-Suite Interview Series with executives from Sanofi, Roche, Eclipse Ventures, BrightInsight and more
Keynote with GenAI demos from BrightInsight CTO, Ashish Agrawal from Google Cloud’s recent GenAI Life Sciences event; watch the YouTube video, (our keynote begins at 1:26:00 - 1:43:20)
White paper on AI in digital health: where to use it and how to unlock value?
Blog: BrightInsight’s Principles for AI
Read our Press release about how BrightInsight is partnering with Google Cloud to modernize its development processes and patient companion apps with Google’s Gemini models, MedLM, and Vertex AI
We hope you find this content valuable, and welcome your feedback on other GenAI topics you want us to cover!